Human Genome 8 and mRNA vaccine
https://www.brighteon.com/59e20408-8324-4a1f-9de5-9c4f9d205394
video: blob:https://www.brighteon.com/1fb538b8-85ba-4c9e-a480-80df2d091e4a
Details about human genome 8: primary assembly and how the mRNA vaccine could change the genome to cause anomalies.
Sources:
https://lbry.tv/@thecrowhouse:2/Do-NOT-Take-The-COVID-Vaccine!:6
The study Zaks cites at the 3:12 minute mark (rumble video next post) can be found and read here. The abstract is contained on the NIH Pub Med Library website. In the full test of the study on ResearchGate, the mention of “Luciferase” occurs on page 10. A crucial piece of information in this study is contained on page 4 – “Ferrets immunized with 200 micrograms and challenged [exposed to influenza H7N9 via IN (intranasal)] on day 49 had viral loads below the level of detection”. If a viral load was “below the level of detection”, two questions emerge: 1) did the ferrets even contract H7N9 through intranasal challenge; and, 2) if a viral load is below the level of detection, how do you know the animals even had a viral load? This would bring into question the efficacy of the injection.
Moreover, the studies Zaks cites as occurring in humans only lasted approximately 18 months.
At about the 4:00 minute mark, Zaks begins discussing mRNA vaccines for cancer. Immediately following that, Zaks discusses a children’s condition where a gene or “code” is missing that causes production of a certain enzyme critical for metabolism where the current treatment is to transplant an entire organ – in this case, the liver. Zaks proposes to inject mRNA that codes for the missing gene, a gene contained in DNA on the human genome, it would “correct” the genetic defect.
Ask this question: what causes the cells/body to produce needed enzymes/proteins? Zaks answers that by saying the genetic code or DNA. So, mRNA has to alter a genetic code or the DNA for the body to produce the proteins of COVID-19 for the body to mount an immune response.
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
https://archive.is/GvUjj#selection-1649.33-1649.147
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5475249/pdf/main.pdf
Abstract
Recently, the World Health Organization confirmed 120 new human cases of avian H7N9 influenza in China resulting in 37 deaths, highlighting the concern for a potential pandemic and the need for an effective, safe, and high-speed vaccine production platform. Production speed and scale of mRNA-based vaccines make them ideally suited to impede potential pandemic threats. Here we show that lipid nanoparticle (LNP)-formulated, modified mRNA vaccines, encoding hemagglutinin (HA) proteins of H10N8 (A/Jiangxi-Donghu/346/2013) or H7N9 (A/Anhui/1/2013), generated rapid and robust immune responses in mice, ferrets, and nonhuman primates, as measured by hemagglutination inhibition (HAI) and microneutralization (MN) assays. A single dose of H7N9 mRNA protected mice from a lethal challenge and reduced lung viral titers in ferrets. Interim results from a first-in-human, escalating-dose, phase 1 H10N8 study show very high seroconversion rates, demonstrating robust prophylactic immunity in humans. Adverse events (AEs) were mild or moderate with only a few severe and no serious events. These data show that LNP-formulated, modified mRNA vaccines can induce protective immunogenicity with acceptable tolerability profiles.
https://www.brighteon.com/59e20408-8324-4a1f-9de5-9c4f9d205394
video: blob:https://www.brighteon.com/1fb538b8-85ba-4c9e-a480-80df2d091e4a
Details about human genome 8: primary assembly and how the mRNA vaccine could change the genome to cause anomalies.
Sources:
https://lbry.tv/@thecrowhouse:2/Do-NOT-Take-The-COVID-Vaccine!:6
The study Zaks cites at the 3:12 minute mark (rumble video next post) can be found and read here. The abstract is contained on the NIH Pub Med Library website. In the full test of the study on ResearchGate, the mention of “Luciferase” occurs on page 10. A crucial piece of information in this study is contained on page 4 – “Ferrets immunized with 200 micrograms and challenged [exposed to influenza H7N9 via IN (intranasal)] on day 49 had viral loads below the level of detection”. If a viral load was “below the level of detection”, two questions emerge: 1) did the ferrets even contract H7N9 through intranasal challenge; and, 2) if a viral load is below the level of detection, how do you know the animals even had a viral load? This would bring into question the efficacy of the injection.
Moreover, the studies Zaks cites as occurring in humans only lasted approximately 18 months.
At about the 4:00 minute mark, Zaks begins discussing mRNA vaccines for cancer. Immediately following that, Zaks discusses a children’s condition where a gene or “code” is missing that causes production of a certain enzyme critical for metabolism where the current treatment is to transplant an entire organ – in this case, the liver. Zaks proposes to inject mRNA that codes for the missing gene, a gene contained in DNA on the human genome, it would “correct” the genetic defect.
Ask this question: what causes the cells/body to produce needed enzymes/proteins? Zaks answers that by saying the genetic code or DNA. So, mRNA has to alter a genetic code or the DNA for the body to produce the proteins of COVID-19 for the body to mount an immune response.
Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
https://archive.is/GvUjj#selection-1649.33-1649.147
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5475249/pdf/main.pdf
Abstract
Recently, the World Health Organization confirmed 120 new human cases of avian H7N9 influenza in China resulting in 37 deaths, highlighting the concern for a potential pandemic and the need for an effective, safe, and high-speed vaccine production platform. Production speed and scale of mRNA-based vaccines make them ideally suited to impede potential pandemic threats. Here we show that lipid nanoparticle (LNP)-formulated, modified mRNA vaccines, encoding hemagglutinin (HA) proteins of H10N8 (A/Jiangxi-Donghu/346/2013) or H7N9 (A/Anhui/1/2013), generated rapid and robust immune responses in mice, ferrets, and nonhuman primates, as measured by hemagglutination inhibition (HAI) and microneutralization (MN) assays. A single dose of H7N9 mRNA protected mice from a lethal challenge and reduced lung viral titers in ferrets. Interim results from a first-in-human, escalating-dose, phase 1 H10N8 study show very high seroconversion rates, demonstrating robust prophylactic immunity in humans. Adverse events (AEs) were mild or moderate with only a few severe and no serious events. These data show that LNP-formulated, modified mRNA vaccines can induce protective immunogenicity with acceptable tolerability profiles.
